S&P 500
(-0.38%) 5 051.09 points
Dow Jones
(-0.38%) 38 358 points
Nasdaq
(-0.29%) 15 650 points
Oil
(-0.74%) $82.74
Gas
(-5.74%) $1.708
Gold
(-0.23%) $2 336.60
Silver
(-0.35%) $27.27
Platinum
(-0.92%) $914.30
USD/EUR
(0.16%) $0.936
USD/NOK
(0.85%) $11.00
USD/GBP
(0.12%) $0.804
USD/RUB
(-0.98%) $92.28

Echtzeitaktualisierungen für Sanofi American [SNY]

Börse: NASDAQ Sektor: Healthcare Industrie: Drug Manufacturers—General
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-04-25)

Expected move: +/- 1.97%

BUY
73.47%
return 8.77%
SELL
32.00%
return 4.33%
Zuletzt aktualisiert24 Apr 2024 @ 18:38

-2.31% $ 46.59

KAUFEN 1308 min ago

@ $47.72

Ausgestellt: 23 Apr 2024 @ 20:50


Rendite: -2.36%


Vorheriges Signal: Apr 22 - 21:52


Vorheriges Signal: Verkaufen


Rendite: 1.44 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 18:38):
Our systems believe the stock currently is undervalued by 0.30% compare to its pairs and should correct upwards.
Profile picture for Sanofi American Depositary Shares (Each repstg one-half of one)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
Tagesvolumen 705 883
Durchschnittsvolumen 1.95M
Marktkapitalisierung 109.16B
EPS $0 ( 2024-02-01 )
Nächstes Ertragsdatum ( $0.970 ) 2024-04-25
Last Dividend $1.903 ( 2023-05-30 )
Next Dividend $0 ( N/A )
P/E 20.34
ATR14 $0.975 (2.09%)
Korrelation (AI algo v.1.1b): Undervalued: 0.30% $46.75 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

Volumen Korrelation

Lang: -0.87 (strong negative)
Kurz: -0.48 (neutral)
Signal:(42) Neutral

Sanofi American Korrelation

10 Am meisten positiv korreliert
PPH0.936
PWOD0.93
ACAHU0.925
WLFC0.914
NWFL0.914
EVOP0.913
ROST0.91
SGHT0.909
HZNP0.907
MGI0.907
10 Am meisten negativ korreliert
LNSR-0.936
MEDS-0.922
VS-0.919
LHDX-0.915
STRC-0.912
TIL-0.911
QLGN-0.91
ULBI-0.91
PLMR-0.909
SG-0.909

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Sanofi American Korrelation - Währung/Rohstoff

The country flag -0.84
( strong negative )
The country flag -0.77
( moderate negative )
The country flag 0.00
( neutral )
The country flag -0.50
( neutral )
The country flag -0.83
( strong negative )
The country flag 0.78
( moderate )

Sanofi American Finanzdaten

Annual 2023
Umsatz: $43.07B
Bruttogewinn: $26.50B (61.52 %)
EPS: $4.31
Q4 2023
Umsatz: $22.88B
Bruttogewinn: $14.68B (64.16 %)
EPS: $1.570
Q3 2023
Umsatz: $12.70B
Bruttogewinn: $8.86B (69.75 %)
EPS: $2.01
Q2 2023
Umsatz: $10.68B
Bruttogewinn: $7.41B (69.41 %)
EPS: $2.74

Financial Reports:

No articles found.

Sanofi American Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$3.28
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Sanofi American Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.30 - Increase likely (45.99%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.462 2003-05-28
Last Dividend $1.903 2023-05-30
Next Dividend $0 N/A
Payout Date 2023-06-23
Next Payout Date N/A
# dividends 24 --
Total Paid Out $33.25 --
Avg. Dividend % Per Year 3.34% --
Score 4.99 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 7.30
Div. Directional Score 9.72 --
Next Divdend (Est)
(2025-02-10)
$1.985 Estimate 3.15 %
Dividend Stability
0.25 Very Poor
Dividend Score
4.99
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2003 $0.462 1.49%
2004 $0.610 1.60%
2005 $0.799 2.01%
2006 $0.912 2.00%
2007 $1.145 2.48%
2008 $1.510 3.31%
2009 $1.419 4.34%
2010 $1.627 3.99%
2011 $1.822 5.55%
2012 $1.756 4.72%
2013 $1.862 3.89%
2014 $1.910 3.69%
2015 $1.618 3.55%
2016 $1.630 3.86%
2017 $1.577 3.84%
2018 $1.861 4.30%
2019 $1.739 4.06%
2020 $1.753 3.46%
2021 $1.906 3.91%
2022 $2.04 4.02%
2023 $3.28 6.69%
2024 $0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1391.5007.2310.00[0 - 0.5]
returnOnAssetsTTM0.06271.2007.919.49[0 - 0.3]
returnOnEquityTTM0.1081.5009.9210.00[0.1 - 1]
payoutRatioTTM0.579-1.0004.21-4.21[0 - 1]
currentRatioTTM1.2670.8008.666.93[1 - 3]
quickRatioTTM0.8270.8009.847.87[0.8 - 2.5]
cashRatioTTM0.3601.5009.1110.00[0.2 - 2]
debtRatioTTM0.132-1.5007.80-10.00[0 - 0.6]
interestCoverageTTM9.291.0007.677.67[3 - 30]
operatingCashFlowPerShareTTM8.202.007.2710.00[0 - 30]
freeCashFlowPerShareTTM5.602.007.2010.00[0 - 20]
debtEquityRatioTTM0.225-1.5009.10-10.00[0 - 2.5]
grossProfitMarginTTM0.6781.0002.032.03[0.2 - 0.8]
operatingProfitMarginTTM0.2601.0006.806.80[0.1 - 0.6]
cashFlowToDebtRatioTTM0.6151.0007.697.69[0.2 - 2]
assetTurnoverTTM0.4520.800-0.322-0.258[0.5 - 2]
Total Score12.14

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM14.121.0008.670[1 - 100]
returnOnEquityTTM0.1082.509.9510.00[0.1 - 1.5]
freeCashFlowPerShareTTM5.602.008.1310.00[0 - 30]
dividendYielPercentageTTM3.981.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM8.202.007.2710.00[0 - 30]
payoutRatioTTM0.5791.5004.21-4.21[0 - 1]
pegRatioTTM0.6451.5009.030[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1801.0008.010[0.1 - 0.5]
Total Score7.30

Sanofi American

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.